Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates

1 Cell‐surface expression of CD40 in B‐cell malignancies and multiple solid tumors has raised interest in its potential use as a target for antibody‐based cancer therapy. SGN‐40, a humanized monoclonal anti‐CD40 antibody, mediates antibody‐dependent cytotoxicity and inhibits B‐cell tumor growth in v...

Ausführliche Beschreibung